• Publications
  • Influence
NF-kappa B as a therapeutic target in multiple myeloma.
TLDR
It is demonstrated that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression
TLDR
Data identify COX‐2 and TNF‐α as operative in the early signature pathologies of diabetic retinopathy, a newly recognized inflammatory disease.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
TLDR
The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
TLDR
It is found that MM cells are irreversibly committed to cell death within few hours of incubation with SAHA, which highlights the pleiotropic antitumor effects of HDAC inhibition, and provides the framework for future clinical applications of SAHA to improve patient outcome in MM.
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
TLDR
SAHA sensitized MM.1S cells to death receptor-mediated apoptosis and inhibited the secretion of interleukin 6 induced in bone marrow stromal cells (BMSCs) by binding of MM cells, suggesting that it can overcome cell adhesion-mediated drug resistance.
NF-κB as a Therapeutic Target in Multiple Myeloma*
TLDR
These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.
TLDR
It is suggested that adiponectin may act as a biomarker of carcinogenesis and may constitute a molecular link between obesity and breast cancer.
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
TLDR
Preclinical studies suggest that TRAIL/Apo2L can overcome conventional drug resistance and provide the basis for clinical trials of TRAIL-based treatment regimens to improve outcome in patients with MM.
...
...